智翔金泰(688443.SH)发预亏，预计2025年年度归母净亏损4.81亿元至5.87亿元

Core Viewpoint - Zhixiang Jintai (688443.SH) forecasts a net loss attributable to shareholders of the parent company for 2025, estimated between -480.64 million to -587.45 million yuan, representing a year-on-year reduction in losses by 209.83 million to 316.64 million yuan, or a decrease of 26.32% to 39.71% compared to the previous year [1] Group 1: Financial Performance - The company's operating revenue has significantly increased compared to the same period last year, primarily due to steady sales growth of its first commercial product, Saliqi monoclonal antibody injection (Jinlixi®), and revenue from the licensing agreement for GR1803 injection [1] - The forecasted net loss for 2025 indicates a substantial improvement in financial performance compared to the previous year [1] Group 2: Research and Development - The company continues to focus on original innovation and efficiently advancing the progress of various research projects, with multiple products entering clinical research and core products entering critical clinical trial phases [1] - The company maintains a high level of R&D investment in its ongoing projects, reflecting its commitment to innovation [1] - The stock incentive plan implemented for the core team in 2022 will expire in 2024, resulting in a reduction of corresponding expenses in 2025 [1]